Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Lisdexamfetamine Dimesylate: Linear Dose‐Proportionality, Low Intersubject and Intrasubject Variability, and Safety in an Open‐Label Single‐Dose Pharmacokinetic Study in Healthy Adult Volunteers

Abstract

The pharmacokinetics of lisdexamfetamine dimesylate, a long‐acting prodrug stimulant, and its active moiety, d‐amphetamine, including dose‐proportionality and variability, were assessed in 20 healthy adults. Subjects received a single dose, sequentially, of 50, 100, 150, 200, and 250 mg of lisdexamfetamine dimesylate. Plasma lisdexamfetamine dimesylate and d‐amphetamine were measured before dosing and 0.25 to 96 hours postdose. Dose‐proportionality and intersubject and intrasubject variability of pharmacokinetic parameters were examined. Safety assessments included adverse events. All 20 subjects received 50 and 100 mg while 18, 12, and 9 subjects received 150, 200, and 250 mg of lisdexamfetamine dimesylate, respectively. Ten subjects were discontinued during the study for prespecified stopping rules (2 consecutive hourly readings of blood pressure: systolic >160 mm Hg or diastolic >100 mm Hg). Mean maximum observed plasma concentration (C max) and area under the concentration—time curve from time 0 to infinity (AUC 0‐∞) increased linearly and dose‐dependently for d‐amphetamine. Median time to C max ranged from 4 to 6 hours for d‐amphetamine and 1.0 to 1.5 hours for lisdexamfetamine dimesylate. Intersubject and intrasubject variability over doses from 50 to 150 mg was low (<20%) for both C max and AUC 0‐∞. Adverse events included nausea, dizziness, headache, psychomotor hyperactivity, and dysuria. These findings indicate that the pharmacokinetic parameters of d‐amphetamine were dose‐proportional and predictable over a wide range of lisdexamfetamine dimesylate doses.

Overview

Integrity signals

Registry

Crossref · 10.1177/0091270009357346

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 21 references

Research works printed but not linked: 1

  1. Boellner S, Dose‐proportionality and safety of lisdexamfetamine dimesylate in children with attention‐deficit/hyperactivity disorder, Clin Ther

Cited by

See all 75

Metadata

Authors
Ermer, J., Homolka, R., Martin, P., Buckwalter, M., Purkayastha, J., & Roesch, B.
Affiliations
Takeda (United States) (US)
Corresponding author
Ermer, James
Venue
The Journal of Clinical Pharmacology
Publisher
Wiley
Published
2010-09
Volume
50
Issue
9
Pages
1001-1010
ISSN
  • 0021-9754 (ISSN-L)
  • 0091-2700
  • 1552-4604
OpenAlex
W2012950683
Cited by
72
References
21
Citations by year
2026: 1 · 2024: 5 · 2023: 2 · 2022: 2 · 2021: 3 · 2020: 1 · 2019: 1 · 2018: 4 · 2017: 5 · 2016: 7 · 2015: 6 · 2014: 8 · 2013: 7 · 2012: 6
FWCI
5.45
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Pharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
Keywords
lisdexamfetamine dimesylate, d-amphetamine, pharmacokinetics, dose proportionality, interindividual variability, within-person variability, stimulants, prodrugs, single-dose administration, adverse events, blood pressure
MeSH terms
Lisdexamfetamine Dimesylate, Adult, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Blood Pressure, Dextroamphetamine, Dose-Response Relationship, Drug, Electrocardiography, Female, Headache, Humans, Male, Middle Aged, Prodrugs, Pulse, Area Under Curve, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lisdexamfetamine Dimesylate: Linear Dose‐Proportionality, Low Intersubject and Intrasubject Variability, and Safety in an Open‐Label Single‐Dose Pharmacokinetic Study in Healthy Adult Volunteers. https://app.cochat.ai/papers/10.1177/0091270009357346
The paper
Ermer, J., Homolka, R., Martin, P., Buckwalter, M., Purkayastha, J., & Roesch, B. (2010). Lisdexamfetamine Dimesylate: Linear Dose‐Proportionality, Low Intersubject and Intrasubject Variability, and Safety in an Open‐Label Single‐Dose Pharmacokinetic Study in Healthy Adult Volunteers. The Journal of Clinical Pharmacology. https://doi.org/10.1177/0091270009357346

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.